carbon tetrachloride has been researched along with olmesartan in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| El-kashef, HA; Ibrahim, TM; Shaaban, AA; Shaker, ME; Zalata, KR | 1 |
| Ge, X; Wang, SN; Wu, Y; Zhang, CQ | 1 |
3 other study(ies) available for carbon tetrachloride and olmesartan
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Modulation of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis by olmesartan and omega-3.
Topics: Actins; Animals; Biomarkers; Carbon Tetrachloride; Drug Therapy, Combination; Fatty Acids, Omega-3; Hydroxyproline; Imidazoles; Liver; Liver Cirrhosis, Experimental; Male; Oxidative Stress; Rats; Rats, Wistar; Receptor, Platelet-Derived Growth Factor beta; Tetrazoles; Transforming Growth Factor beta1 | 2014 |
Olmesartan Improves Hepatic Sinusoidal Remodeling in Mice with Carbon Tetrachloride-Induced Liver Fibrosis.
Topics: Angiotensin II; Animals; Carbon Tetrachloride; Collagen; Imidazoles; Interleukin-10; Liver Cirrhosis; Mice; Neovascularization, Pathologic; Tetrazoles; Vascular Endothelial Growth Factor A | 2022 |